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Background:  Since  August  2014,  an increase  in  infections  caused  by  enterovirus  D68 (EV-D68)  was
reported  in  the  USA  and  Canada,  for the  most  part  in  children  presenting  with  severe  respiratory  symp-
toms.
Objectives:  To determine  whether  an  increase  in severe  EV-D68  respiratory  infections  was  observed  in
our region.
Study  design:  Samples  from  patients  with  respiratory  symptoms  were  screened  for viral pathogens,
including  rhinovirus  and  enterovirus.  Subsequently,  samples  positive  for rhinovirus  and  enterovirus  were
routinely  sequenced  for  phylogenetic  analysis.  Furthermore,  an  additional  method  was  used  to  detect
EV-D68  speciﬁcally.
Results: During  the  ﬁrst  three  quarters  of  the  year  2014,  1896  respiratory  samples  were  analyzed;  39
(2%)  of  them  tested  positive  for enterovirus.  Eighteen  samples  tested  positive  for  EV-D68,  obtained  from
16 different  patients  admitted  to our hospital.  Eleven  were  children  below  the  age  of  18,  of  whom  ﬁve
children  needed  intensive  care  treatment.  The  remaining  ﬁve  samples  were  from  adults,  who  all  had
an  underlying  disease;  three  were  transplant  patients  (heart,  lung  and  renal  transplantation),  the  other
two  had  an  underlying  lung  condition  (COPD,  asthma).  Phylogenetic  analysis  showed  a  close  relationship
with  the  strains  circulating  currently  in  the  USA,  all belonging  to the  known  EV-D68  genetic subtypes.
Conclusions:  We  observed  an  increase  of EV-D68  infections  in our population,  both  in  children  as  well  as
in  adult.  In 2014  there  have  been  16  cases  so  far,  compared  to none  in  2011  and  2013  and  a  single  case
in  2012.  Phylogenetic  analysis  identiﬁed  two  similar  clusters  as  shown  in  the USA  and  Canada.
© 2014  The  Authors.  Published  by  Elsevier  B.V.  This  is  an  open  access  article  under the  CC  BY-NC-ND. Background
Since August 2014, an increase in infections caused by
nterovirus D68 (EV-D68) has been reported in the USA and Canada.
n this outbreak, the majority of samples analyzed are from children
ith severe respiratory illness, many of whom have symptoms of
heezing. Also, some fatalities have been documented [1].
In the years 2009 and 2010, our hospital in the Northern partf the Netherlands was confronted with an increase in respira-
ory illness, which was not only seen in our tertiary care hospital,
ut also regionally [2]. An outbreak of EV-D68 was shown to
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386-6532/© 2014 The Authors. Published by Elsevier B.V. This is an open access article unlicense (http://creativecommons.org/licenses/by-nc-nd/3.0/).
be the cause of the increased incidence of respiratory infections.
Because EV-D68 was not detected by our routine respiratory
panel at that time, we added an enterovirus PCR into our routine
screening panel of 14 respiratory viruses (Inﬂuenza A, Inﬂuenza B,
parainﬂuenzavirus 1–4, coronaviruses OC43, NL63 and 229E, ade-
novirus, bocavirus, RSV-A, RSV-B and human metapneumovirus).
Moreover, we  expanded our testing by routinely sequencing all
enterovirus and rhinovirus strains to identify virus strains and to
chart outbreaks and transmission patterns. Adding to this sequenc-
ing strategy, we  included noroviruses as well as parechoviruses.
Nationally, a structure called TYPENED was  available through the
Dutch National Institute of Health (RIVM) [3]. Furthermore, by
using our regional sequencing and epidemiological strategy, called
REGIOTYPE, we were able to speed up the ﬂow of information from
our region, including hospitals and Public Health Services covering
the (not densely populated) Northern part of the Netherlands. The
aim of this REGIOTYPE strategy is to provide a rapid sequencing
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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ervice for the whole region. This not only completes our diagnos-
ics with sequencing data, but as clinical data are fed back into our
atabase, we create a source of information which serves to obtain
ore insights in epidemiology patterns.
Recently, the European Center for Disease prevention and Con-
rol (ECDC) concluded in a “rapid risk assessment” [4] that no
pidemic clusters of severe disease caused by EV-D68 in EU/EEA
ountries were observed and that a moderate risk of EV-D68 was
xpected. The ECDC rapid risk assessment attributes the low level of
eporting of EV-D68 to the low number of laboratories which rou-
inely screen respiratory samples for EV-D68. Subsequently, only a
mall number of EV-D68 cases (11) are observed in the Netherlands
uring the enterovirus ‘peak season’ in 2014, through both the
ntero-surveillance and the ILI/ARI surveillance networks [5]. How-
ver, we are observing an increase in infections caused by EV-D68 in
ur tertiary care hospital since May  2014, similar to the outbreak in
he USA and Canada. To improve the speciﬁc diagnostics for EV-68,
e developed a speciﬁc real-time PCR method.
. Objectives
To determine the circulation of EV-D68 in our region, during a
ime when an outbreak of this virus is ongoing in North America,
nd to develop an EV-D68 speciﬁc PCR method.
. Study design
.1. Patients and sample collection
Samples from patients with respiratory symptoms, are routinely
creened for several viruses, including inﬂuenza A and B, RSV type
 and B, metapneumovirus, parainﬂuenzavirus type 1–4, coronavi-
us (OC43, 229E and NL63), adenovirus, bocavirus, rhinovirus and
nterovirus. During the ﬁrst three quarters of the year 2014, 1896
espiratory samples were analyzed. Samples that tested positive
or enterovirus were selected for sequencing.
.2. Detection of enterovirus/rhinovirus
All primary patient materials sent to our laboratory for analy-
is of respiratory viruses, are routinely screened for rhinovirus and
nterovirus by a laboratory developed real-time PCR that ampli-
es a 116 bp fragment of the 5′ NTR region of both rhinovirus
nd enterovirus. Differentiation between both viruses is done by
he use of highly speciﬁc probes containing locked nucleic acids
LNA) at the 5′ terminus (Table 1). RNA was extracted from 190 l
ample with the addition of 10 l Internal Control, phocine dis-
emper virus (PDV), using the NucliSense EasyMag (bioMérieux,
yon, France). PCR was performed in a total reaction volume
f 25 l using 10 l RNA, 1xTaqMan® Fast Virus 1-Step Master
able 1
rimers and probes for RT-PCR and sequencing of enterovirus D68.
PCR Oligo Sequence (5′ → 3′) 
Rhinovirus/enterovirus
RT-PCR
HRVHEVfw CGGCCCCTGAATGYGG 
Rhi-asense TGGAAACACGGACACCCAA 
HEV1-lna-pr4 Cy5-YGTGGCGGAACCGA-BHQ3 
HEV2-lna-pr2 Cy5-YGCAGCGGAACCGACT-BHQ3 
Rhino-lna-pr2 FAM-YGGGAYGGGACCAACT-BHQ1 
IC  RT-PCR PDV fwd CGGGTGCCTTTTACAAGAAC 
PDV rev TTCTTTCCTCAACCTCGTCC 
PDV MGB  NED NED-AAGGGCCAATTC-MGB 
EV-D68 speciﬁc
RT-PCR
EV-D68 FW TGTTCCCACGGTTGAAAACAA 
EV-D68 RV TGTCTAGCGTCTCATGGTTTTCAC 
EV-D68 Probe VIC-TCCGCTATAGTACTTCG-MGB 
EV-D68 Probe VIC-ACCGCTATAGTACTTCG-MGB cal Virology 62 (2015) 1–5
Mix  (Applied Biosystems, Foster City, CA, USA), 750 nM forward
and reverse primer for Rhinovirus/Enterovirus, 250 nM Rhinovirus
probe, 125 nM Enterovirus probe each, 300 nM forward and reverse
primer for PDV, 100 nM probe for PDV and DNase/RNase free water
(Sigma). Reactions were run on an ABI7500 using the proﬁle of
2 min  50 ◦C, 20 s 95 ◦C, followed by 45 cycles of 3 s 95 ◦C and 32 s
60 ◦C.
3.3. Sequencing strategies and phylogenetic analysis
Rhinovirus and enterovirus positive samples were routinely
typed by sequencing. Identiﬁcation of the rhinovirus strains was
done by ampliﬁcation and sequencing of a 549 nucleotide fragment
spanning the hyper variable part of the 5′ NTR, the entire VP4 gene
and the 5′ terminus of the VP2 gene with primers described by
Savolainen et al. [6]. Identiﬁcation of the enterovirus strains was
done by ampliﬁcation and sequencing of 350–400 basepairs part of
the VP1 gene as has been described by Nix et al. [7].
An automated DNA sequencer was  used (ABI 3130XL). Sequence
data were analyzed with Sequencing Analysis (version 5.3; ABI)
and subsequently phylogenetic analysis was performed using
BioNumerics Software 6.6 (Applied Maths, Sint-Martens-Latem,
Belgium).
3.4. -Development of an EV-D68 speciﬁc real-time PCR
To support initiatives for the rapid and speciﬁc detection of EV-
D68, a Real-Time PCR was developed for fast detection of EV-D68.
Primers and probes were developed using a ClustalW2.0 alignment
of all currently available 5′ Non Coding Region (NCR) sequences
in the NCBI database and Primer Express 3.0 software (Applied
Biosystems).
Twenty-two samples, spanning a period from 2010 to 2014,
previously detected by RT-PCR and identiﬁed with EV-D68 by
sequencing, were tested for validation. For determining speciﬁcity,
six currently circulating human rhinovirus (HRV) strains of the
genogroups A, B and C (HRV-A38, HRV-A43, HRV-B17, HRV-B70,
HRV-C2 and HRV-C18) and 11 samples from 2014 containing dif-
ferent enterovirus species (CV-A2, CV-A4, CV-A6, CV-A10, CV-A11,
CV-B4, E-3, E-16, E-25, EV-C105 and EV-C117) were included in
testing, as well as ﬁve reference strains provided by the Dutch
National Institute of Health (CV-A12, CV-A15, E-5, E-11 and the
EV-D68 reference Fermon strain).
Sample types included were sputum, nasopharynx, ﬂocked
swab, stool and cerebrospinal ﬂuid.
RNA was extracted as described previously. PCR was performed
in a total reaction volume of 25 l using 10 l RNA, 1xTaqMan®
Fast Virus 1-Step Master Mix  (Applied Biosystems, Foster City,
CA, USA), 600 nM forward and reverse primer for EVD68, 200 nM
EV-D68 probe each (Table 3) and DNase/RNase free water (Sigma).
Target Orientation Reference
5′ NTR rhinovirus/enterovirus Sense primer LDT
5′ NTR rhinovirus/enterovirus Anti-sense primer LDT
5′ NTR enterovirus Probe LDT
5′ NTR enterovirus Probe LDT
5′ NTR rhinovirus Probe LDT
Haemagglutinine PDV Sense primer Clancy et al. [10]
Haemagglutinine PDV Anti-sense primer Clancy et al. [10]
Haemagglutinine PDV Probe Clancy et al. [10]
5′ NTR EVD68 Sense primer LDT
5′ NTR EVD68 Anti-sense primer LDT
5′ NTR EVD68 Probe LDT
5′ NTR EVD68 Probe LDT
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Table  2
Patient characteristics of patients admitted with EV-D68 in chronological order.
Patient Sex Age Date Symptoms ICU/days Underlying condition
1 F 1y/11m February 2014 Moderate bronchiolitis-type
respiratory illness
No None
2  F 1y/7m May  2014 Severe respiratory illness,
intubation, mechanical ventillation
Yes/4 None
3  F 6m June 2014 Mild cold symptoms No Congenital heart disease
4  M 3y/9m June 2014 Severe respiratory illness,
intubation, mechanical ventillation
Yes/8 Sickle-cell anemia
5  M 65y July 2014 Moderate wheezing and cough No Lung transplantation
6  M 1y July 2014 Severe respiratory illness,
intubation, mechanical ventillation
Yes/5 None
7  M 3y/10m July 2014 Severe respiratory illness,
intubation, mechanical ventillation
Yes/1 Ex-premature
8  M 6m August 2014 Mild cold symptoms a Congenital heart disease
9  M 14y August 2014 Mild cold symptoms a Traumatic brain injury
10  F 1y/6m August 2014 Mild cold symptoms No Epilepsy
11  M 1m August 2014 Severe respiratory illness,
intubation, mechanical ventillation
Yes/1 Ex-premature
12  F 22y August 2014 Cough, SOB, fatigue No Heart transplantation
13  F 44y August 2014 Cough, SOB No COPD
14  M 1y/5m September 2014 Moderate wheezing, cough No Tracheomalacia, congential heart disease
15  F 63y September 2014 Asthma exacerbation No Asthma
16  F 53y September 2014 Wheezing, pneumonia No Kidney transplantation
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assay was  designed in the 5′ NCR. All clinical samples of 2014 which
tested positive in the standard EV assay and subsequently typed as
EV-D68, were also tested positive in the EV-D68 speciﬁc PCR.
Table 3
Enteroviruses detected from respiratory samples, UMCG 2014.
Genotype Number of samples
CV-A4 1
CV-A6 5
CV-A16 1
CV-B1 1
CV-B4 1
E-16 4
E-18 1
E-25 2
EV-C104 1
EV-C105 1OB, shortness of breath.
a These patients were admitted to ICU for reasons other than respiratory illness.
eactions were run on a ABI7500 as follows: 15 min  50 ◦C, 20 s
5 ◦C, followed by 45 cycles of 5 s 95 ◦C, 5 s 50 ◦C and 45 s 60 ◦C.
. Results
Since the beginning of 2014, 1896 respiratory samples were
ested, of which 39 (2%) were positive for enterovirus. Eighteen
amples tested positive for EV-D68, obtained from 16 different
atients admitted to our hospital. (Table 2). Eleven cases were
hildren of whom ﬁve presented with severe respiratory illness,
equiring intubation and mechanical ventilation. Of these ﬁve
everely ill children, two (aged 1 year and 1 year/7 months) had
een previously healthy and two were ex-prematures (aged 3
ears/10 months and 1 month). One of the previously healthy
hildren (patient 6) was given resuscitation prior to admission to
he pediatric intensive care unit. One child had sickle cell anemia
s underlying condition (3 years/9 months). Two  children were
dmitted with a moderately severe bronchiolitis-type respiratory
nfection with wheezing and shortness of breath. Four children
ad mild respiratory infections with common cold-symptoms
nly. These children all had underlying conditions for which they
ere admitted to our hospital. Interestingly, two of these chil-
ren (patient 8 and 9) acquired the infection several days after
dmission. The sequences of these isolates were identical with the
equence of patient 7 (GenBank Accession numbers: KM887895,
M887898 and KM887899). Both patient 8 and 9, were admitted to
he same pediatric intensive care unit during the same period as the
dmission of patient 7, which suggests nosocomial transmission.
Five cases of EV-D68 infections were from adults. All adult
atients had underlying conditions predisposing them to respi-
atory tract infections. One patient was a heart transplantation
atient, one was a lung transplant patient, one was a kidney trans-
lantation patient, one had asthma and one had chronic obstructive
ulmonary disease (COPD). All ﬁve adults had to be admitted to
he hospital with symptoms of cough, shortness of breath and
heezing. The patient with a kidney transplant (patient 16) hadadiological signs compatible with pneumonia.
In all 16 cases, the diagnosis of EV-D68 infection was  made
ollowing a positive PCR result for enterovirus and subse-
uent sequencing. EV-D68 partial VP1 sequences were submittedto GenBank, accession numbers: KM887894–KM887906 and
KM924544–KM924547.
4.1. Epidemiological information since 2009
We tested 1896 respiratory samples in our laboratory during
the ﬁrst three quarters in 2014. 39 (2%) samples were tested posi-
tive for enterovirus. Different enterovirus types were isolated, of
which 18 samples were EV-D68 (Table 3). The upsurge of EV-
D68 corresponds with the regular enterovirus season period in
2014. A similar upsurge occurred in 2009 and 2010, with a peak
in September and October. However, in 2011 and 2013, there were
no EV-D68 observations at all, while in 2012 only one respiratory
sample contained EV-D68 (Fig. 1).
4.2. EV-D68 speciﬁc real-time PCR
The EV-D68 test was highly speciﬁc, all strains were tested neg-
ative for types other than EV-D68 as described in Section 2. TheEV-D68 18
NDa 3
Total 39
a ND, not deﬁned.
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during a time period while a large EV-D68 outbreak took place in
F
[Fig. 1. EV-D68 occurrence in the UMCG 2009–2014.
.3. Sequence data and information
Phylogenetic analysis shows that 3 out of the 17 sequences cor-
espond with clade A and 14 out of 17 sequences with clade B, as
escribed by Tokarz et al. [8]. None of our sequences corresponded
ith clade C. USA strains correspond with both, clade A and clade B,
ig. 2. Phylogenetic tree EV-D68 2009–2014. Node colors – purple: 2009, red: 2010, yello
8].cal Virology 62 (2015) 1–5
suggesting that similar strains are currently circulating in the USA
and Europe (Fig. 2).
5. Discussion
In this paper, we presented 16 cases of respiratory EV-D68 infec-
tions in the Northern part of the Netherlands in 2014. These patients
were in most cases admitted to the hospital because of a seri-
ous respiratory illness. Of these 16 cases, ﬁve were children with
a life-threatening respiratory illness. We also noted ﬁve EV-D68
infections in adults, all with underlying conditions, predisposing
to more severe respiratory illness. Three were transplantation
patients and two had pulmonary conditions. All of these ﬁve adults
required hospital care for respiratory infections.
This upsurge of respiratory infections caused by EV-D68 was
similar to what was  seen in our hospital in 2009 and 2010 [2]. More
importantly, the 2014 EV-D68 upsurge in our hospital occurredthe USA and Canada, involving around a thousand children. Also
in the USA, only the children admitted to the hospital were tested
and reported. We  expect that the number in North America could be
w: 2011, light blue: 2012, green: 2014. Clades A, B and C as deﬁned by Tokarz et al.
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igher if the adult population with severe respiratory illness were
ncluded.
The incidence of EV-D68 observed in our hospital, which is
ocated in the least densely populated part of the Netherlands, is
ontrasted by the low number of reported EV-D68 infections in
est of the Netherlands, while no data are known about the current
ituation in Europe [4,5]. After all, it seems unlikely that EV-D68
s causing problems only in the USA, Canada and the Northern
art of Netherlands, without affecting other European regions. In
he 2009–2010 upsurge, a number of children became severely ill.
oreover, it was then shown that 21% of the cases were hospital
cquired, which highlights the need for testing of not only patients
ith severe respiratory disease, but also patients with mild symp-
oms, who may  spread the virus. Similarly, in the current 2014
tudy, we possibly witnessed in-hospital transmission of EV-D68
rom one severely ill child to two children who developed mild
espiratory symptoms.
The low number of reported EV-D68 infections in Europe may
e caused by the overall low circulation of EV-D68. However, it
ould also be caused by the under-diagnosis of EV-D68 infections
ue to insufﬁcient sampling of patients with respiratory illness, or
n insufﬁcient detection of this virus in routine screening panels,
hether using Laboratory Developed Tests (LDTs) or commercial
ssays. From QCMD quality assurance data, it is known that the
espiratory virus testing performed in a number of laboratories
ailed to detect EV-D68 (Dr. Paul Wallace, personal communication,
CMD, Glasgow, United Kingdom).
The recent ECDC report claims that the circulation of EV-D68 in
urope is low, thus has to be viewed in the context of a near absent
etection of this pathogen [4]. In addition, the potential for under-
ampling has to be considered. Although no exact data exists on
nderdiagnoses as yet, it is our experience that clinicians, at least
n the Netherlands, are discouraged from performing diagnostic
ests for patients presenting with probable viral illnesses because
f ﬁnancial constraints. And if testing is done, only inﬂuenza virus
nd RSV are preferably tested.
A recent initiative by the European Society for Clinical Virology
ESCV) in collaboration with the ECDC was started to investigate
he prevalence of EV-D68 in Europe. Further epidemiological infor-
ation is needed on a larger scale than currently available to
etermine the circulation for this virus. The implicit risk of focusing
n a limited number of viruses for diagnostic purposes, or not per-
orming virological diagnostics at all, is contestable. Patients with
n underlying disease, whether children, transplant patients, or
atient with a chronic respiratory condition, are not getting optimal
are if the diagnostic options are limited or even absent. Therefore, a
iagnostic stewardship program should be discussed asides antimi-
robial stewardship and an infection control programs, which are
urrently being introduced in many hospitals [9]. We  have doc-
mented upsurges of EV-D68 associated with sometimes severe
orbidity twice in the last 5 years, i.e. in 2009/2010 and in 2014. It
an be anticipated that the virus will reappear regularly and there-
ore diagnostic assays, whether LDTs or commercial assays, should
e able to detect this virus. The EV-D68 speciﬁc assay we  describe
n this paper, may  be used for this purpose.
All 16 cases described in this paper were diagnosed as EV-
68 infections by following routine protocols of our laboratory, in
[cal Virology 62 (2015) 1–5 5
which respiratory samples are tested for enterovirus along with 14
other respiratory targets, and all enterovirus isolates are routinely
sequenced. Our sequencing data, compared to the USA sequence
data, suggest that similar strains are circulating in the USA  and
Europe.
In conclusion, by following a routine protocol of screening
respiratory samples for enterovirus and sequencing, we  not only
identiﬁed EV-D68 as the cause of 16 respiratory infections in
our hospital, but we also were able to show a potential link
with the ongoing EV-D68 in North-America. EV-D68 is associated
with at times severe respiratory illness. Adequate surveillance for
viruses like EV-D68 which can cause severe respiratory illnesses,
is therefore desirable for University Medical Centers and Reference
Centers. A collaborative approach effort between the diagnostic and
reference laboratories could be taken to achieve this. The EV-D68
speciﬁc assay we present in this paper may  aid in the assessment of
the real prevalence of this virus in our population, both in children
and adults.
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